375 related articles for article (PubMed ID: 33614507)
1. Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities.
Eddy K; Shah R; Chen S
Front Oncol; 2020; 10():626129. PubMed ID: 33614507
[TBL] [Abstract][Full Text] [Related]
2. Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma.
Isola AL; Eddy K; Chen S
Cancers (Basel); 2016 Dec; 8(12):. PubMed ID: 27941674
[TBL] [Abstract][Full Text] [Related]
3. Oxidative-Stress-Sensitive microRNAs in UV-Promoted Development of Melanoma.
Pecorelli A; Valacchi G
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804995
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies.
Didier R; Mallavialle A; Ben Jouira R; Domdom MA; Tichet M; Auberger P; Luciano F; Ohanna M; Tartare-Deckert S; Deckert M
Mol Cancer Ther; 2018 Jul; 17(7):1416-1429. PubMed ID: 29703842
[TBL] [Abstract][Full Text] [Related]
5. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
Yeon M; Kim Y; Jung HS; Jeoung D
Front Cell Dev Biol; 2020; 8():486. PubMed ID: 32626712
[TBL] [Abstract][Full Text] [Related]
7. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
8. Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies.
Mattia G; Puglisi R; Ascione B; Malorni W; Carè A; Matarrese P
Cell Death Dis; 2018 Jan; 9(2):112. PubMed ID: 29371600
[TBL] [Abstract][Full Text] [Related]
9. UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer.
Liu-Smith F; Jia J; Zheng Y
Adv Exp Med Biol; 2017; 996():27-40. PubMed ID: 29124688
[TBL] [Abstract][Full Text] [Related]
10. Molecular biology of normal melanocytes and melanoma cells.
Bandarchi B; Jabbari CA; Vedadi A; Navab R
J Clin Pathol; 2013 Aug; 66(8):644-8. PubMed ID: 23526597
[TBL] [Abstract][Full Text] [Related]
11. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
12. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
13. Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes.
Kim Y; Gil J; Pla I; Sanchez A; Betancourt LH; Lee B; Appelqvist R; Ingvar C; Lundgren L; Olsson H; Baldetorp B; Kwon HJ; Oskolás H; Rezeli M; Doma V; Kárpáti S; Szasz AM; Németh IB; Malm J; Marko-Varga G
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32213878
[TBL] [Abstract][Full Text] [Related]
14. Other targeted drugs in melanoma.
González-Cao M; Rodón J; Karachaliou N; Sánchez J; Santarpia M; Viteri S; Pilotto S; Teixidó C; Riso A; Rosell R
Ann Transl Med; 2015 Oct; 3(18):266. PubMed ID: 26605312
[TBL] [Abstract][Full Text] [Related]
15. Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches.
Motofei IG
Curr Treat Options Oncol; 2019 May; 20(6):45. PubMed ID: 31056729
[TBL] [Abstract][Full Text] [Related]
16. Genetic progression of malignant melanoma.
Tímár J; Vizkeleti L; Doma V; Barbai T; Rásó E
Cancer Metastasis Rev; 2016 Mar; 35(1):93-107. PubMed ID: 26970965
[TBL] [Abstract][Full Text] [Related]
17. Signaling and Immune Regulation in Melanoma Development and Responses to Therapy.
Lin WM; Fisher DE
Annu Rev Pathol; 2017 Jan; 12():75-102. PubMed ID: 27959628
[TBL] [Abstract][Full Text] [Related]
18. Roles of UVA radiation and DNA damage responses in melanoma pathogenesis.
Khan AQ; Travers JB; Kemp MG
Environ Mol Mutagen; 2018 Jun; 59(5):438-460. PubMed ID: 29466611
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.
Koppolu V; Rekha Vasigala VK
J Cancer Res Ther; 2018; 14(6):1167-1175. PubMed ID: 30488824
[TBL] [Abstract][Full Text] [Related]
20. A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma.
Jackett LA; Scolyer RA
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31861163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
